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Abstract
Introduction: Anti-citrullinated peptide antibodies are found in rheumatoid arthritis (RA) patients with HLA-DRb
chains encoding the shared epitope (SE) sequence. Citrullination increases self-antigen immunogenicity, through
increased binding affinity to SE-containing HLA-DR molecules. To characterise T-cell autoreactivity towards
citrullinated self-epitopes, we profiled responses of SE+ healthy controls and RA patients to citrullinated and
unmodified epitopes of four autoantigens.
Methods: We compared T-cell proliferative and cytokine responses to citrullinated and native type II collagen 1,237
to 1,249, vimentin 66 to 78, aggrecan 84 to 103 and fibrinogen 79 to 91 in six SE+ healthy controls and in 21 RA
patients with varying disease duration. Cytokine-producing cells were stained after incubation with peptide in the
presence of Brefeldin-A.
Results: Although proliferative responses were low, IL-6, IL-17 and TNF were secreted by CD4+ T cells of SE+ RA
patients and healthy controls, as well as IFNg and IL-10 secreted by RA patients, in response to citrullinated
peptides. Of the epitopes tested, citrullinated aggrecan was most immunogenic. Patients with early RA were more
likely to produce IL-6 in response to no epitope or to citrullinated aggrecan, while patients with longstanding RA
were more likely to produce IL-6 to more than one epitope. Cytokine-producing CD4+ T cells included the
CD45RO+ and CD45RO- and the CD28+ and CD28- subsets in RA patients.
Conclusion: Proinflammatory cytokines were produced by CD4+ T cells in SE+ individuals in response to
citrullinated self-epitopes, of which citrullinated aggrecan was most immunogenic. Our data suggest that the T-cell
response to citrullinated self-epitopes matures and diversifies with development of RA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease
characterised by inflammation of joint synovial tissue
and deformity and destruction of associated bone, carti-
lage and soft tissues. Several autoantigens are described
in RA, including a variety of proteins that become
citrullinated in diseased joints. Citrullination is a physio-
logical process of arginine deimination that occurs dur-
ing apoptosis and inflammation. This process results in
modification of arginine-containing proteins, which can
give rise to sets of neo-self-antigens in individuals bear-
ing at-risk HLA alleles [1].
Specific HLA-DR gene variants mapping to amino
acids 70 to 74 of the third hypervariable region of DRb
chains are highly associated with RA [2]. This region
encodes a conserved amino acid sequence that forms
the fourth anchoring pocket (P4) in the HLA-DR anti-
gen-binding groove. This shared susceptibility epitope
(SE) is found in multiple RA-associated DR alleles,
including DRB1*0401, DRB1*0404 and DRB*0101 in
Caucasians [2]. The SE-encoding HLA alleles are parti-
cularly associated with anti-citrullinated protein autoan-
tibody (ACPA)-positive RA [3-5]. The SE is highly
positively charged, and is situated in a region of the
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DRb chain that influences the specificity of the P4
amino acid of the bound ligand. The SE would therefore
preferentially bind peptides containing a negatively
charged or nonpolar amino acid at this position.
Citrullination replaces charged arginine amino side-
chain groups with an uncharged carbonyl group, and
has been shown to be permissive of binding of a human
vimentin peptide epitope to SE+ HLA DR molecules
through increased affinity with P4 [6,7]. While the
dominant B-cell vimentin, fibrinogen and collagen type
II epitopes in RA are citrullinated, evidence is just emer-
ging that T cells show specificity towards citrullinated
over the corresponding native epitopes [7].
Approximately 70% of RA patient sera contain ACPAs
[8]. This reactivity reflects autoantibody production
towards a group of citrullinated autoantigens modified
post-translationally, including fibrinogen, vimentin, col-
lagen type II and enolase [9]. ACPAs develop up to 15
years prior to the onset of RA, with increasing titres and
peptide reactivities as disease onset becomes imminent
[10]. Citrullinated proteins have been demonstrated in
inflamed tissues in RA, and ACPAs are induced in a
number of mouse models of inflammatory arthritis
[11-14]. Although citrullination is ubiquitous in
response to stress and inflammation, ACPAs are highly
specific for RA and are associated with more severe
joint damage and radiographic outcome [3,4,8].
Immunisation of HLA-DRB1*0401 transgenic mice
with citrullinated fibrinogen, but not native fibrinogen,
induced inflammatory arthritis characterised by simulta-
neous B-cell and T-cell autoreactivity to citrullinated
and native HLA-DR-restricted fibrinogen epitopes,
which was not present in naïve HLA-DRB1*0401 trans-
genic mice [15]. Furthermore, recent studies suggest
that delivery of the costimulation modulator, abatacept,
may restore tolerance towards citrullinated antigens
[16]. Notwithstanding these studies in transgenic mice,
citrulline-specific autoreactive T cells have been difficult
to demonstrate in RA patients due to the weak prolif-
erative responses made by autoreactive effector memory
T cells in vitro. However, several recent papers have
shown convincing cytokine responses made by RA
patient T cells in response to citrullinated vimentin and
aggrecan epitopes [7,17]. In the case of vimentin, the
immunogenicity of the epitope was dependent on the
location of the citrulline modification within the peptide
sequence [7].
In the current studies, we profiled the responses of SE
+ healthy controls and RA patients towards a set of
citrullinated and unmodified (native) self-antigens, and
characterised the responding T cells. Our aim was to
identify citrullinated epitopes that may be of particular
relevance in ACPA+ RA, and to determine the extent of
individual variability among citrullinated autoantigenic
T-cell responses. Further, we wished to identify T cells
that may contribute to the development of ACPA+ RA.
Of four citrullinated autoantigenic peptides, we identi-
fied citrullinated aggrecan 84 to 103 as the most immu-
nogenic, and we identified IL-6 production by T cells as
an important biomarker of response.
Materials and methods
Patients
Twenty-one patients who fulfilled the 1987 American
College of Rheumatology criteria for RA [18] and six
ACPA- SE+ healthy controls were included. All indivi-
duals provided peripheral blood (PB) samples, although
in some cases the yield was insufficient for all assays.
Patient demographic details are outlined in Table 1.
HLA-DR genotyping was carried out at Queensland
Health Pathology Services. The study was approved by
the Human Research Ethics Committee of the Princess
Alexandra Hospital and informed consent was obtained
from each patient.
Peptide preparation
Citrulline or arginine-containing SE-binding epitopes
were synthesised from vimentin, collagen type II, fibri-
nogen and aggrecan (Auspep Tullamarine VIC, Austra-
lia). All peptides were filtered, reconstituted to 300 μg/
ml in sterile water and stored at -70°C. Final dilutions
for the working stock were made with medium.
Purification of peripheral blood mononuclear cells and
antigen presentation assays
Peripheral blood mononuclear cells (PBMC) were isolated
using Ficoll-Paque density gradients (GE Healthcare, Pis-
cataway, New Jersey, United States), washed with 0.9% sal-
ine and then resuspended in RPMI containing 10% human
serum from healthy or autologous or allogeneic RA
donors. Tetanus toxoid was used at a concentration of 4
Lfi/ml (Chiron Vaccines, Mumbai, Maharashtra, India).
Two × 105 PBMC or SFMC were incubated with 0, 3 and
30 μg/ml of each peptide in the presence of RPMI con-
taining 10% human serum in a final volume of 200 μl in
round-bottomed wells for 5 days. T-cell proliferation was
assessed by addition of 1 μCi/well [3H]thymidine (ICN
Biochemicals Costa Mesa, CA, USA) for the final 18
hours. Cells were harvested onto glass-fibre filter mats and
[3H]thymidine incorporation was determined by liquid
scintillation spectroscopy (Packard Topcount; Packard
Instrument Co. Meridien, CT, USA). IL-2, IL-4, IFNg, IL-
10, IL-6, IL-17 and TNF were measured in the day 5
supernatants using BD Cytometric Bead Array kits (BD
Bioscience, San Jose, CA, USA).
Initial kinetic experiments demonstrated that peptide
stimulation for 5 days optimally induced antigen-specific
proliferative and cytokine responses, and that longer
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cultures did not yield greater responses. Where RA
serum was used in cytokine production assays, 150 μg/
ml HeteroBlock (Omega Biologicals Bozeman, MT,
USA) were added during BD Cytometric Bead Array
measurement [19]. Samples were read on the BD FAC-
SArray™ bioanalyser system.
Stimulation indices for proliferative responses were
calculated as the fold increase in response to peptide
over background. Net cytokine secretion was calculated
for each response as the concentration with peptide sti-
mulation minus the concentration without peptide sti-
mulation. Positive response thresholds were two
standard deviations above the cytokine responses
towards the corresponding native peptide, for both RA
patients and healthy controls.
Flow cytometry and intracellular cytokine staining
PBMC from SE+ RA patients or healthy controls were
incubated without or with peptides at concentrations
of 3 and 30 μg/ml for 5 days, with Brefeldin-A (Sigma
Aldrich St Louis, MO, USA) added for the final 18
hours. Cells were stained for CD3-FITC, CD4-APC/
Cy7, CD28-FITC, CXCR5-PerCP/Cy5.5 and CD45RO-
PerCP/Cy5.5 (Biolegend, San Diego, CA, USA), fol-
lowed by permeabilisation and staining for intracellular
IL-6-APC and IFNg-APC (Biolegend). Data were col-
lected on the Gallios flow cytometer and analysed
using Kaluza software (Beckman Coulter, Indianapolis
IN, USA).
Statistical analysis
One-way nonparametric analysis of variance with post-
hoc correction (Kruskal-Wallis test) compared multiple
means. Unpaired Mann-Whitney tests compared the
tetanus toxoid proliferative responses between RA
patients and healthy controls and compared specific
cytokine responses with citrullinated versus native pep-
tides. Significance is indicated as P < 0.05, P < 0.01 and
Table 1 Characteristics of patients in the study
Patient Ethnicity HLA-DRB1
genotype
ACPA Disease duration
(years)
Treatment C-reactive proteina (mg/
l)
Representation
RA1 Caucasian 03,0401 + 6 M, S 8 Figure 1
RA2 Caucasian 03, 0401 + < 1 Nil 3 Figures 1 to 5
RA3 Caucasian/Pacific
Islander
0403, 0405 - < 1 M, S, H 3 Figure 1
RA4 Caucasian 0401, 0404 + < 1 L 11 Figures 1 to 5
RA5 Caucasian 0404, 1302 + 1 M, S, H 2 Figure 1
RA6 Caucasian 0401 13 + > 5 M, H 1 Figures 1 to 5
RA7 Asian 0405 - 1 M 1 Figures 1 to 5
RA8 Caucasian 0401, 0404 + > 5 L, H, S 22 Figures 1 to 5
RA9 Caucasian 0103, 0101 + < 1 Nil 4 Figures 1 to 5
RA10 Caucasian 01, 1302 + 5 H 10 Figures 1 to 5
RA11 Caucasian 04, 0301 - 4 M, S, H 3 Figures 1 to 5
RA12 Caucasian 0401 + 0 Nil 45 Figures 1 to 5
RA13 Caucasian 0101, 1301 - > 5 M 20 Figures 1 to 6
RA14 Caucasian 0408, 11 + > 5 M, S, H 4.6 Figures 1 to 6
RA15 Caucasian 0401, 0408 + 0 Nil 1 Figures 1 to 6
RA16 Caucasian 0101, 0408 + 0 Nil 6 Figures 1 to 6
RA17 Caucasian 0401, 03 + > 5 M, A 33 Figure 6
RA18 Caucasian 0401, 03 + 3 M 2 Figures 1 to 5
RA19 Caucasian 0101, 0103 + 2 M, S, H 5.3 Figures 1 to 5
RA20 Caucasian 0401, 1501 + 2 - 9.9 Figures 1 to 5
RA21 Caucasian 0401, 0101 + > 5 M, P 2 Figures 1 to 5
HC1 Caucasian 01 - Figures 1 to 5
HC2 Caucasian 03, 04 - Figures 1 to 5
HC3 Caucasian 0401, 0701 - Figures 1 to 5
HC4 Caucasian 0101, 08 - Figures 1 to 5
HC5 Caucasian 1301, 0401 - Figures 1 to 6
HC6 Caucasian 0401, 1301 - Figures 1 to 6
A, abatacept; ACPA, anti-citrullinated peptide antibody; H, hydroxychloroquine; L, leflunomide; M, methotrexate; S, sulfasalazine; P, prednisone. For rheumatoid
arthritis (RA) patients, mean age is 50 (range 22 to 65), 90% female; for healthy control (HC) individuals, mean age is 38 (40 to 45), 50% female. aMeasured at the
time of blood withdrawal for peptide response.
Law et al. Arthritis Research & Therapy 2012, 14:R118
http://arthritis-research.com/content/14/3/R118
Page 3 of 12
P < 0.001. All error bars represent the standard error of
the mean.
Results
T cells proliferate poorly but produce cytokines in
response to citrullinated autoantigenic peptides
We synthesised citrullinated or unmodified peptide anti-
gens from the fibrinogen, vimentin, collagen type II and
aggrecan protein sequences that had been identified -
either based on predicted binding capacity to RA-asso-
ciated DR molecules in a molecular model positioning
citrulline at P4, or through previous studies in HLA-
DR4-IE-transgenic mice (Table 2) [6,15,17]. In total, we
studied 21 SE+ RA patients and six SE+ healthy controls.
All except four RA patients were also ACPA+ (Table 1).
Forty-three per cent of the RA patients were nonsmo-
kers, 38% past smokers and 19% current smokers. One
healthy control was a current smoker, and two controls
had a family history of RA. We analysed the proliferative
response of PBMC from SE+ RA patients and SE+
healthy controls to varying concentrations of citrulli-
nated or unmodified peptide antigen. Proliferative
responses to peptide antigens and tetanus toxoid were
expressed as stimulation indices. The mean proliferative
stimulation indices to citrullinated and unmodified pep-
tides were generally between 1 and 2 in RA patients and
healthy controls, and were significantly lower in each
case than the responses to tetanus toxoid (Figure 1).
The proliferative stimulation indices in response to
citrullinated aggrecan peptide were significantly higher
than those to native aggrecan peptide in RA patients
(Figure 1). Proliferative responses to tetanus toxoid were
significantly lower when comparing RA PBMC with
healthy control PBMC.
In initial experiments we determined that background
cytokine secretion and proliferative responses were gen-
erally lower if peptide responses were assayed in the
presence of human rather than foetal calf serum. More-
over, there was no difference in cytokine production
when comparing assays carried out in the presence of
10% healthy or autologous or allogeneic RA donor
serum, provided HeteroBlock was added when rheuma-
toid factor titres were > 100 U/ml (data not shown) to
prevent rheumatoid factor from binding capture and
detection antibodies in ELISA reactions [19]. In the
absence of peptide stimulation, RA patient PBMC
secreted significantly higher concentrations of IFNg and
IL-6 than of TNF and IL-10, secreted by either RA
patients or healthy controls in the absence of peptides
(Figure 2A). Net cytokine secretion was estimated as
cytokine secreted upon stimulation with citrullinated
peptides minus cytokine secreted in the absence of pep-
tides. IL-6 secretion was highest of the cytokines mea-
sured, with net production of up to 60 ng/ml in
response to 30 μg/ml citrullinated aggrecan.
Consistent with the lack of binding of native epitopes
to shared epitope HLA-DR alleles [7] (and unpublished
data), RA patients produced significantly greater
amounts of IL-6, TNF and IL-10 in response to citrulli-
nated than native aggrecan peptides (Figures 2B and 3).
IL-17 and to some extent IFNg were also secreted in
response to several citrullinated peptides, but there was
considerable variability among individuals and none of
the differences was statistically significant (Figure 3). IL-
2 and IL-4 responses were generally low (data not
shown). When comparing RA patients and healthy con-
trols, RA patients secreted significantly more IL-10 and
TNF in response to citrullinated aggrecan than healthy
controls (P < 0.05), and there was a similar trend for IL-
17 secretion in response to citrullinated aggrecan (P =
0.065) and citrullinated fibrinogen (P = 0.08).
Given the lack of stable HLA-DR binding of native
self-peptides, we determined positive responses to citrul-
linated peptides to be greater than a threshold of the
mean and two standard deviations above responses to
the corresponding native peptides (citrullinated vimentin
responses could not be assessed as responses to native
vimentin were not measured). When compared with SE
+ healthy controls, SE+ RA patients’ citrullinated peptide
responses produced a more diverse array of cytokines.
Notably, when the percentage of RA patients and
healthy controls with positive responses to each citrulli-
nated peptide was plotted, the regulatory cytokines IL-
10 and IFNg were only produced by RA patients for the
tested epitopes (Figure 4).
IL-6 response among RA patients varies with disease
duration
To better understand the citrullinated peptide response
pattern of individual RA patients and SE+ healthy con-
trols, we plotted IL-6 dose-response curves for each
peptide for each individual in the study. PBMC from
Table 2 Sequences of peptides used in the study
Native peptide sequence Citrullinated peptide sequence Human native protein
QDFTNRINKLKNS QDFTNCitINKLKNS Fibrinogen-a 79 to 91
VVLLVATEGRVRVNSAYQDK VVLLVATEGCitVRVNSAYQDK Aggrecan 84 to 103
SAVRARSSVPGVR SAVRACitSSVPGVR Vimentin 66 to 78
QYMRADQAAGGLR QYMCitADQAAGGLR Collagen II 1,237 to 1,249
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Figure 1 T-cell proliferative response of healthy controls and rheumatoid arthritis patients stimulated with peptides. Peripheral blood
mononuclear cells (PBMC) from 20 rheumatoid arthritis (RA) patients and six healthy controls were incubated with 0, 3 or 30 μg/ml citrullinated
(cit) and native peptides or 4 Lfi/ml tetanus toxoid, as shown, for 5 days. T-cell proliferation was assessed by uptake of [3H]thymidine. Each dot
represents one individual. ***P < 0.001 for RA patients and **P < 0.01 for healthy controls comparing multiple means (Kruskal-Wallis test). **P <
0.01 comparing healthy controls and RA patient PBMC for the response to tetanus toxoid (Mann-Whitney test). *P < 0.05 comparing RA patients’
responses to citrullinated and native aggrecan peptides (Mann-Whitney test). SI, stimulation indices.
Figure 2 Unstimulated cytokine secretion and net IL-6 secretion by peripheral blood mononuclear cells stimulated with peptides. (A)
Peripheral blood mononuclear cells (PBMC) from 17 rheumatoid arthritis (RA) patients and six healthy controls were incubated in medium for 5
days and cytokines were assessed in supernatants by the BD Cytometric Bead Array. **P < 0.01, *P < 0.05 (Kruskal-Wallis test with post-hoc
correction). (B) PBMC from 17 RA patients and six healthy controls were incubated with 0, 3 or 30 μg/ml citrullinated (cit) and native peptides as
shown, and IL-6 was assessed in supernatants by the BD Cytometric Bead Array. Net cytokine secretion was calculated as the IL-6 concentration
with peptide stimulation minus the IL-6 concentration without peptide stimulation. Each dot represents one individual. *P < 0.05, **P < 0.01
comparing IL-6 responses with citrullinated and native peptides (Mann-Whitney test).
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four out of six healthy controls dose-dependently
secreted IL-6 to citrullinated aggrecan and PBMC from
three out of six controls secreted IL-6 in response to
citrullinated fibrinogen. Taking the same threshold for a
positive response as described above, we found that six
out of 17 RA patients’ PBMC responses secreted IL-6 in
Figure 3 Net cytokine secretion by peripheral blood mononuclear cells stimulated with citrullinated and native peptides. Net TNF, IFNg,
IL-10 and IL-17 secretion by peripheral blood mononuclear cells from 17 rheumatoid arthritis (RA) patients and six healthy controls incubated
with 0, 3 or 30 μg/ml citrullinated (cit) and native peptides as shown. Cytokines were assessed in supernatants by the BD Cytometric Bead Array.
Net cytokine secretion was calculated as in Figure 2B. Each dot represents one individual. *P < 0.05, comparing IL-10 responses with citrullinated
and native aggrecan (Mann-Whitney test).
Figure 4 Representation of cytokines produced by rheumatoid arthritis patients and healthy controls. The percentage of rheumatoid
arthritis (RA) patients or of healthy controls with positive responses (> 2 standard deviations (SD) above the mean response towards the
corresponding native peptide) was calculated for each cytokine, and is plotted for responses to citrullinated (cit) fibrinogen, aggrecan and
collagen type II.
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response to no epitopes, eight patients’ responses to
citrullinated aggrecan only, none to citrullinated fibrino-
gen, none to citrullinated collagen type II only and three
patients’ responses to > 1 citrullinated epitope. IL-6
responses were thus highest and observed most fre-
quently towards citrullinated aggrecan in both RA
patients and healthy controls, suggesting this was the
most immunogenic epitope tested. An IL-6 response to
> 1 citrullinated epitope occurred more frequently
among patients diagnosed with RA at least 5 years pre-
viously (Figure 5B).
Effector memory CD4+ T cells secrete cytokines in
response to citrullinated peptides
IL-6 is an important cytokine in RA, which could be
produced upon stimulation of PBMC by either T cells
or antigen-presenting cells. To determine the origin of
the cytokines secreted into supernatants of PBMC sti-
mulated by citrullinated peptides, we incubated RA
PBMC with citrullinated or native peptides for 5 days,
and with addition of Brefeldin-A for the last 18 hours,
prior to intracellular cytokine staining along with analy-
sis of cell surface markers. CD3+CD4+ T cells produced
more intracellular IFNg and IL-6 when incubated with
citrullinated aggrecan or fibrinogen relative to incuba-
tion in medium alone (Figure 6A, B).
Fluorescence minus one staining demonstrates the
gating strategy to determine the threshold for positive
staining, as described elsewhere [20] (Figure 6C). No
intracellular cytokine staining was observed in these
assays by CD4-CD28- cells, most of which represent
antigen-presenting cells (Figure 6D). Differentiated or
ageing CD45RO- memory cells have been shown to re-
express CD45RA and to be characterised by the loss of
CD27 and CD28 [21]. In healthy controls, CD28- cells
comprised only a small proportion of the CD4+ T cells,
and cytokine-secreting cells were exclusively CD4+CD28
+. CD28- cells were more abundant among CD4+ PB T
Figure 5 Diversity of citrullinated peptide-reactive IL-6 response among rheumatoid arthritis patients and healthy controls. (A)
Peripheral blood mononuclear cells from 17 rheumatoid arthritis (RA) patients and six healthy controls were incubated with 0, 3 or 30 μg/ml
citrullinated (cit) and native peptides as shown, and each individual’s IL-6 response in supernatant was plotted. Disease duration and HLA type
are indicated. (B) The frequency of RA patients with either recent-onset or longstanding disease with positive responses (> 2 standard deviations
(SD) above the mean response towards the corresponding native peptide) for each peptide is shown. ACPA, anti-citrullinated peptide antibody.
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cells in some, but not all, RA patients. Where CD4
+CD28- T cells were present, IL-6 and IFNg were
secreted by both CD28- and CD28+CD4+ T cells in
response to citrullinated peptides. We noted high back-
ground cytokine secretion in these cultures, as we had
observed earlier in analysis of supernatants (Figures 2A
and 6A). IFNg+CD4+ and IL-6+CD4+ T cells included
both CD45RO+ and CD45RO- cells (Figure 6E). CXCR5
+ follicular helper T cells did not express IL-6 or IFNg
in response to citrullinated peptides (data not shown).
Discussion
We have shown here that proinflammatory and regula-
tory cytokines, including IL-6, IFNg IL-10 and TNF,
were produced by CD4+ T cells in SE+ RA patients in
response to citrullinated self-epitopes, of which citrulli-
nated aggrecan was most immunogenic. These cytokine
responses were observed in spite of weak peptide-speci-
fic T-cell proliferative responses. SE+ healthy controls
also produced cytokines in response to citrullinated
aggrecan and citrullinated fibrinogen. Such T-cell
responses are not necessarily causally related to RA -
rather, they demonstrate the autoreactivity present in SE
+ individuals towards citrullinated self-peptides, even in
the absence of ACPAs. Cytokine responses to citrulli-
nated self-epitopes, however, were more diverse in RA
patients than in healthy control individuals. Indeed, only
RA patients secreted the regulatory cytokines IL-10 and
IFNg in response to these epitopes [22]. IFNg produc-
tion by PB and synovial T cells is well described [23],
and IFN-regulated genes have been shown to be predic-
tive of RA development in ACPA+ patients with arthral-
gia [24]. Using intracellular staining we demonstrated
IL-6 and IFNg production by memory CD4+ T cells but
Figure 6 Cytokine secretion by CD4+ T-cell subsets. Peripheral blood mononuclear cells (PBMC) from HLA-DR SE+ rheumatoid arthritis (RA)
patients and healthy controls were incubated with 0 or 30 μg/ml citrullinated (cit) fibrinogen or citrullinated aggrecan, stained with mAb
directed against (A) CD4, CD28, IFNg and IL-6 or (E) CD4, CD45RO, IL-6 and IFNg, and then analysed by flow cytometry. (B) The gating strategy is
outlined. FS, forward scatter; SS, side scatter. (C) Fluorescence minus one (FMO) plot showing background staining for intracellular cytokine
staining, gated on CD4+ T cells. (D) IL-6 staining of gated CD4- non-T cells. The proportions in (E) of IL-6+CD4+CD45RO+ T cells were 2.2%, 5.3%
and 7.1%, and of IL-6+CD4+CD45RO- T cells were 0.8%, 2.1% and 4% in response to incubation with no peptide, citrullinated fibrinogen and
citrullinated aggrecan, respectively. Two individual RA patients and one healthy control are shown. Data are representative of two healthy
donors and five RA patients.
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not by CD4- antigen-presenting cells in these cultures,
at least when examined after 5 days of peptide stimula-
tion. These data demonstrate that CD4+ T cells were
capable of cytokine production but do not exclude the
possibility that CD4- antigen-presenting cells such as
monocytes, B cells and dendritic cells could also pro-
duce these cytokines during the culture, which could be
secreted into the supernatant. IL-6 responses increased
dose-dependently in response to citrullinated peptides.
Intracellular cytokine staining confirmed a broad cyto-
kine response profile, consistent with the phenotype of
memory CD4+ T cells.
Various mechanisms could contribute to the low pro-
liferative response exhibited by autoreactive T cells to
self-peptides and tetanus toxoid antigen in RA. For
instance, a number of studies implicate deficient signal-
ling of RA T cells through the T-cell receptor-CD3
complex [25-31]. IL-2 might be rapidly consumed
through binding to the high avidity CD25 receptor
expressed by regulatory T cells and by effector memory
T cells upon activation. This could limit availability of
IL-2 for T-cell proliferation in tissue culture [32,33].
Furthermore, autoreactive T cells are subject to the
influence of regulatory cells and cytokines, as demon-
strated here [34,35]. On the other hand, effector mem-
ory cells produce high levels of proinflammatory and
regulatory cytokines, and cytokine production more
effectively interrogates highly differentiated autoreactive
effector memory T cells in both humans and mice
[36-38].
The proinflammatory cytokine IL-6 stimulates B-cell
antibody production and plays a critical role in RA
pathogenesis [39]. In RA patients, intracellular IL-6 and
IFNg were produced by CD28+ and CD28- and CD45RO
+ and CD45RO- PB CD4+ T cells. Consistent with the
poor proliferative but good cytokine response of RA T
cells in response to citrullinated peptides in the current
studies, CD4+CD45RBdimCD27- memory T cells from
healthy donors were previously shown to proliferate
poorly but to produce large amounts of IL-4 and IL-10
in response to mitogen, and to provide effective B-cell
help for immunoglobulin production [40]. In contrast,
typical CXCR5+ follicular helper T cells, which have
been shown to promote antibody production in lym-
phoid tissue in vivo [41], did not express cytokines in
response to citrullinated peptides. Of interest, where
CD28- T cells were present in PB of RA patients, they
also produced cytokine in response to citrullinated pep-
tides. CD28- T cells represent an important effector
memory amplification response in the synovial environ-
ment, and have been shown to be more resistant to sup-
pression by regulatory T cells [21,42]. Together our data
support the hypothesis that effector memory T cells,
reactive with a variety of citrullinated self-peptides and
with the potential for B-cell help, circulate in PB of SE+
individuals.
Previous studies in RA patients analysed the PB CD4
+ T-cell response to a single citrullinated peptide spe-
cificity. Proliferative and IL-17 CD4+ T-cell responses
to citrullinated aggrecan 84 to 103 were demonstrated
in RA patients but not in healthy controls, demonstrat-
ing the immunogenicity of this citrullinated aggrecan
epitope [17]. The unmodified aggrecan epitope is
immunodominant in BALB/c mice immunised with
aggrecan/proteoglycan [43]. This citrullinated aggrecan
peptide was also the most immunogenic epitope in the
current studies - with the highest frequency of respon-
ders, and with the highest magnitude of IL-6
responses. In longstanding RA patients, we also found
robust cytokine production in response to citrullinated
fibrinogen-a 79 to 91, which was shown to be the
immunodominant epitope in HLA-DR4-IE transgenic
mice immunised with citrullinated human fibrinogen
[15].
Stimulation with the citrullinated vimentin 66 to 78
epitope produced much weaker cytokine responses in
the current studies - as was observed by Snir and collea-
gues, who found that HLA-DRB1*0401+ RA patient T
cells produced a number of cytokines when incubated
with citrullinated vimentin 59 to 78 but not citrullinated
vimentin 66 to 78 [7]. In that study, IFNg and TNF
were expressed intracellularly by a small proportion of
CD154+CD4+ RA patient T cells in response to citrulli-
nated but not native vimentin 59 to 78. The proportion
of T cells staining for intracellular cytokine was much
lower than in the current studies, in which we carried
out staining 5 days after antigen stimulation and without
a second restimulation. Anergy may possibly have been
induced by restimulation with peptide after an initial 5-
day culture with peptide - or, given their effector mem-
ory phenotype [44], few T cells were capable of re-
expressing CD154 after prolonged in vitro culture. Simi-
lar to the current study, Snir and colleagues did not
observe strong proliferative or IL-17A responses, unlike
von Delwig and colleagues [17].
Differences in cytokine secretion may relate to the
inclusion of healthy human serum or of HeteroBlock
plus autologous serum in the current studies [19].
Finally, due to the hydrophobic amino acids at 84 to 88,
the citrullinated aggrecan peptide was relatively insolu-
ble in aqueous medium, which may also have affected
the antigen purity, concentration and cellular uptake in
different laboratories. The greater immunogenicity of
citrullinated aggrecan possibly also relates to its length
relative to the other peptides. Structural analysis of the
HLA-DR binding and T-cell contact residues of these
peptides will aid understanding of the T-cell responses
observed.
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We observed T-cell cytokine responses to citrullinated
self-epitopes in SE+ RA patients, whether ACPA+ or
not, as well as in ACPA- healthy controls. HLA-
DRB1*0401+ healthy control T cells were also observed
to produce cytokine in response to citrullinated vimen-
tin 59 to 78 [7]. After immunisation of DR4-IE trans-
genic mice with citrullinated human fibrinogen,
responses to unmodified native epitopes were stimulated
in parallel with responses to citrullinated epitopes. From
the previous and current analyses of HLA-DR binding
and responses to unmodified epitopes, responses to
citrullinated epitopes appear to be most specific to SE+
RA PB. In contrast, the magnitude and diversity of the
responses to citrullinated epitopes in healthy controls
was unexpected. CD4+ T cells in both SE+ RA patients
and HLA-DR4+ healthy controls have reduced T-cell-
receptor excision circles, overall telomere shortening,
and reduced replicative capacity, which together imply
an HLA-DR SE-associated reduction in T-cell input to
the peripheral repertoire, an increased proliferative drive
for naïve T cells towards peripheral self-antigens and a
limited diversity of the TCR repertoire [45-47].
Together, studies in humans suggest that PB T cells in
HLA-DR SE+ individuals may be predisposed to auto-
reactivity towards self-antigens, including those modified
by citrullination, potentially exposed during stress or
proinflammatory settings, including joint trauma or
smoking [3,48]. Furthermore, unlike T-cell autoreactiv-
ity, the development of B-cell autoreactivity towards
citrullinated epitopes appears to be a significant check-
point in the progression to RA. It has been proposed
that infection (for example, with Porphyromonas gingiva-
lis in patients with periodontitis) may be a critical trig-
ger for progress through this checkpoint, potentially due
to cross-reactivity with bacterial antigens, adjuvant
effects of pathogen-associated molecular patterns, tar-
geting of alternative antigen-presenting cells, or a com-
bination of these [9]. Carbamylation of lysine residues to
homocitrulline may be another factor enhancing the
immunogenicity of RA autoantigens, including citrulli-
nated antigens [49].
Our data suggest that RA patients with longstanding
disease may be more likely to respond to more than
one citrullinated epitope, whereas patients with recent-
onset RA (including those previously untreated)
appeared generally to respond either to no antigen or
only to citrullinated aggrecan. These data suggest the
possibility that epitope-spreading occurs as disease
progresses. To confirm this hypothesis, a larger sample
of RA patients would need to be studied, preferably
longitudinally, along with peptide-MHC tetramer reac-
tivity. Furthermore, it would be preferable to study a
panel of the most immunogenic citrullinated epitopes,
including the citrullinated aggrecan and fibrinogen a
epitopes used here, and citrullinated vimentin 59 to 78
[7]. The assay developed here, in which T-cell cytokine
production is interrogated in the presence of varying
concentrations of a panel of citrullinated epitopes, is
likely to be a useful biomarker to identify the most
immunogenic peptide epitopes, and to correlate speci-
fic T-cell responses with corresponding ACPA fine
specificities [50]. These assays would be optimally car-
ried out in conjunction with analysis of tetramer-speci-
fic T cells. Future applications include comparison of
serial samples of PBMC from pre-RA through to diag-
nosis [51], and effects of treatment. The analysis of
PBMC from clinical trials of antigen-specific or non-
specific immunotherapy, such as abatacept, would also
be of interest [16]. Finally, analysis of specific peptide
reactivity may be beneficial for stratifying patients and
for identifying appropriate epitopes for personalised
antigen-specific immunotherapy.
Conclusion
Proinflammatory and regulatory cytokines were pro-
duced by CD4+ T cells in SE-positive individuals in
response to citrullinated self-epitopes, of which citrulli-
nated aggrecan was most immunogenic. Our data sug-
gest that the T-cell response matures and diversifies
with development of RA.
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